PP01.144: Patient-Reported Outcomes (PROs) from IMforte: A Phase 3 Study of First-Line Maintenance Treatment with Lurbinectedin + Atezolizumab Versus Atezolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Year: 2026
Type: conference-abstract
Source: Journal of Thoracic Oncology
Authors: Roy S. Herbst, Luis Paz-Ares, Hossein Borghaei, Stephen V. Liu, Solange Peters, Muhammet Bekir Hacıoğlu, Atike Gokcen Demiray, Adam Płużański, Giannis Mountzios, Athanasios Kotsakis, Stefan Hammerschmidt, Gabriella Gálffy, Eleni Karapanagiotou, Siobhan Connor-Ahmad, Carla Mamolo, Ya-Chen Lin, Jonathon Gable, Debasis Chakrabarti, George Cai, Martin Reck
Institutions: Yale University, Universidad Complutense de Madrid, Hospital Universitario 12 De Octubre, Fox Chase Cancer Center, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Centre Hospitalier Universitaire Vaudois, Trakya University, Pamukkale University, The Maria Sklodowska-Curie National Research Institute of Oncology, University Hospital of Larissa, Klinikum Chemnitz, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, Roche (United Kingdom), Genentech, Jazz Pharmaceuticals (Ireland), German Center for Lung Research, LungenClinic Grosshansdorf
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7160517948